HBV lamivudine resistance among hepatitis B and HIV coinfected patients starting lamivudine, stavudine and nevirapine in Kenya

Autor:	H. N. Kim, Linda S. Cook, Keith R. Jerome, Rhoda Ashley Morrow, Kenneth Tapia, Anne Cent, Godfrey Lule, Barbra A. Richardson, Michael H. Chung, Grace John-Stewart, J. Scott
Rok vydání:	2011
Předmět:	Hepatitis B virus HBsAg Nevirapine Hepatology business.industry Stavudine virus diseases Lamivudine Hepatitis B medicine.disease_cause medicine.disease Lamivudine resistance Virology digestive system diseases Infectious Diseases Medicine business Viral load medicine.drug
Zdroj:	Journal of Viral Hepatitis. 18:e447-e452
ISSN:	1352-0504
Popis:	Widespread use of lamivudine in antiretroviral therapy may lead to hepatitis B virus resistance in HIV-HBV co-infected patients from endemic settings where tenofovir is not readily available. We evaluated 389 Kenyan HIV-infected adults before and for 18 months after starting highly-active antiretroviral therapy with stavudine, lamivudine and nevirapine. Twenty-seven (6.9%) were HBsAg(+) and anti-HBs negative: 24 were HBeAg-negative, 18 had HBV DNA ≤10,000 IU/ml. Sustained HBV suppression to
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::888c82fe5ca61a06a0d294f741086b1e https://doi.org/10.1111/j.1365-2893.2011.01466.x Zobrazit plný text záznamu Plný text ve formátu PDF